A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
25 March 2026
Read original ↗
🅇 This trial is currently recruiting participants in the UK
Speak to your GP or specialist first. They can help you understand if you might be eligible and what taking part would involve.
🔬 This trial is currently recruiting participants
If you match the criteria below, you may be able to take part. Ask your doctor about this trial or contact the trial team directly.
Status
Recruiting
Trial Phase
PHASE1
Who Can Join
ALL
Age Range
18 Years – Any
About This Trial
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:
* The safety of the study treatment and if people tolerate it.
* A safe dose level of I-DXd that can be used with other treatments.
* Participant levels of prostate specific antigen (PSA) during treatment.
Run by
Merck Sharp & Dohme LLC
⚕️ Before you apply: Talk to your GP or specialist about whether this trial might be right for you. Never stop existing treatment without medical advice. Trial ID: NCT06863272